We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+37.6%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$232M
AUM Growth
+$52.7M
Cap. Flow
+$13.9M
Cap. Flow %
6%
Top 10 Hldgs %
61.94%
Holding
59
New
16
Increased
15
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$6.62M
2
WHWK
Whitehawk Therapeutics
WHWK
+$4.21M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.18M
4
BCAB icon
BioAtla
BCAB
+$3.4M
5
UTHR icon
United Therapeutics
UTHR
+$3.24M

Top Sells

Rank Stock Value
1
VTGN icon
VistaGen Therapeutics
VTGN
+$10M
2
RCUS icon
Arcus Biosciences
RCUS
+$4.24M
3
OBIO icon
Orchestra BioMed
OBIO
+$3.91M
4
DTIL icon
Precision BioSciences
DTIL
+$3.28M
5
MRUS
Merus
MRUS
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 90.75%
2 Financials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITOS
51
DELISTED
iTeos Therapeutics
ITOS
– –
-62,000
Closed -$1.28M
OBIO icon
52
Orchestra BioMed
OBIO
$254M
– –
-392,500
Closed -$3.91M
OCUL icon
53
Ocular Therapeutix
OCUL
$2.02B
– –
-13,171
Closed -$53K
RCUS icon
54
Arcus Biosciences
RCUS
$3.64B
– –
-167,500
Closed -$4.24M
VSTM icon
55
Verastem
VSTM
$610M
– –
-16,667
Closed -$232K
VTGN icon
56
VistaGen Therapeutics
VTGN
$12.8M
– –
-378,715
Closed -$10M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Acuta Capital Partners held 59 positions worth $232M, up 29% from $179M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners deployed $13.9M of net new capital in Q3 2022, opening 16 new positions and adding to 15 existing holdings. Its largest new stake was Sarepta Therapeutics: 41,500 shares worth $4.59M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $2.27M trimmed.

  • Acuta Capital Partners's largest Q3 2022 buy was Sarepta Therapeutics: 41,500 shares worth $4.59M.
  • Acuta Capital Partners added most to BELLUS Health Inc. in Q3 2022, an estimated $6.62M increase.
  • Acuta Capital Partners's biggest Q3 2022 reduction was Merus, cutting an estimated $2.27M.
  • Acuta Capital Partners fully exited VistaGen Therapeutics in Q3 2022, selling an estimated $10M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $232M portfolio in Q3 2022.
  • Acuta Capital Partners opened 16 new positions and closed 12 in Q3 2022.
  • Acuta Capital Partners's portfolio value rose 29% quarter-over-quarter to $232M.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.